Neovascularization has a critical role in the growth and metastatic spread of tumors, and involves recruitment of circulating endothelial progenitor cells (EPCs) from bone marrow. In this study, we examined whether EPCs could promote tumor angiogenesis, and found that the tumor growth was enhanced by the administration of EPCs. To test the hypothesis that genetically modified bone marrow-derived EPCs can be effective carriers of therapeutic agents to tumor sites, we conducted human interferon-beta (HuIFN-b) gene transfection of EPCs with a virus vector in vitro. When HuIFN-b was applied in the ex vivo culture of EPCs, HuIFN-b-transduced EPCs achieved efficient killing of the total population of SPC-A1 cells, indicating a bystander effect was elicited by HuIFN-b-transduced EPCs in vitro. When SCP-A1 cancer cells were coimplanted along with ex vivo cultivated EPCs subcutaneous injection in nude mice, the tumor growth was increased. However, the anti-tumor effect of interferon-beta (IFN-b) offset the tumor-progressive character of EPCs and the tumor growth, and the vascular density of tumor tissues increased by coimplanted EPCs were decreased upon IFN-b treatment. In addition, overall expression levels of vascular endothelial growth factor in tumor tissues were decreased upon IFN-b treatment. Therefore, our results suggest that gene-transfected EPCs could be useful as a tumor-specific drug delivery system.
INTRODUCTION
The targeted delivery of a therapeutic gene remains one of the most significant barriers to successful cancer gene therapy. To date, current approaches to gene therapy have had disappointing results, because of the inability to achieve expression of the transgene in different tumor-cell populations and in all tumor-site locations. 1 In view of the constant requirement for vascular supply in solid tumors, and considering that tumor-associated neovascularization involves the recruitment of endothelial progenitor cells (EPCs) as well as endothelial cells to the tumor vasculature, 2 use of EPCs as carriers of therapeutic agents to tumor sites and inhibition of tumor-induced neovascularization have been an effective anticancer approach.
In this study, we utilized separated EPCs to the syngenic rat and conducted human interferon-beta (HuIFN-b) gene transfection of EPCs to test the hypothesis that genetically modified bone marrowderived EPCs can be effective carriers of therapeutic agents to tumor sites, and to confirm whether interferon-beta (IFN-b) inhibited vascular endothelial growth factor (VEGF) secretion of EPCs during tumor vasculature-promoting effect of EPCs in vitro.
RESULTS

EPCs phenotype
After 4 days in culture, mononuclear cells isolated from the patients' blood that exhibited a spindle-shaped endothelial cell-like morphology, adherence and positive staining for both 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine (DiI)-acLDL uptake and lectin binding were characterized as EPCs (Figure 1 ).
Upregulation of HuIFN-b expression in EPCs transduced with HuIFN-b
To investigate the role of HuIFN-b, first we transduced EPCs with the recombinant lentivirus virus encoding the HuIFN-b gene or lentivirus vector. The transduction efficiencies were initially evaluated using qPCR, western blot and enzyme-linked immunosorbent assay (ELISA) analysis. As shown in Figure 2a , the HuIFN-b mRNA levels in transduced EPCs with the recombinant lentivirus virus encoding the HuIFN-b gene displayed a significant promotion when compared with mock or control. In addition, western blot and ELISA analysis showed the responsive changes of HuIFN-b protein levels in corresponding transductants (Figures 2b and c) .
The bystander effect was elicited by HuIFN-b-transduced EPCs in vitro Fundamental to the efficiency of the molecular chemotherapy strategy is the bystander effect, whereby toxin gene-expressing cells exert a noxious effect on surrounding untransduced cells. Thus, we investigated whether the HuIFN-b-expressing EPCs could functionally accomplish a bystander effect with SPC-A1 cells in vitro. A mixing experiment was performed in which HuIFNb-transduced EPCs were mixed at various ratios with SPC-A1 cells measured using a 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. Studies were performed with EPCs to determine whether they could induce bystander cytotoxicity into SPC-A1 cells. In effect, as few as 25% of HuIFN-b-transduced EPCs achieved killing of about 25% of the total population of SPC-A1 cells. Of note, when 50% of HuIFN-b-transduced EPCs cells were mixed with SPC-A1 cells, 460% of the total number of cells died ( Figure 3 ). 
IFN-b inhibits VEGF secretion from EPCs
From the immunohistochemical and western blot analysis of tumor tissues, we found that HuIFN-b administration resulted in downregulation of VEGF expression in SPC-A1 tumor tissues and such effect was especially accentuated in the coimplanted EPCs, which expressed VEGF at a higher level than the tumor cells in vivo (Figures 6a and b) . Thus, we examined whether HuIFN-b would directly inhibit VEGF expression in EPCs using ex vivo cultivation system. Indeed, the level of VEGF secreted by EPCs was 230±12 pg ml À1 by an ELISA assay and such VEGF secretion from EPCs was significantly decreased upon HuIFN-b treatment at 55 ± 8 pg ml À1 (Po0.05) (Figure 6c ), indicating that EPCs promote tumor growth by expression and secretion of VEGF, and HuIFN-b could inhibit tumor growth by decreasing secretion of VEGF. 
DISCUSSION
Neovascularization has a critical role in the growth and metastatic spread of tumors, and involves recruitment of circulating EPCs from bone marrow, as well as sprouting of preexisting endothelial cells. Although there were some discrepancies already reported, the role of EPCs in vessel formation in adult ischemia and tumor has become widely accepted. 3 Thus far, although the identity of EPCs has not been clear yet, the ex vivo cultivated EPCs, which already commit to differentiation at some levels, have been also proved to contribute to tumor vessel formation. 4, 5 Ex vivo cultivated EPCs derived from mononuclear cells of human peripheral blood or cord blood have been successfully shown to incorporate into neovasculature and contribute to functional recovery of ischemic tissue. 6, 7 In this study, we examined whether EPCs could promote tumor angiogenesis and found that the tumor growth was enhanced by the administration of EPCs. It is suggested that accumulated EPCs differentiated to tumor vasculature, increased the tumor blood supply, and thereby increased the tumor volume. To test the hypothesis that genetically modified bone marrow-derived EPCs can be effective carriers of therapeutic agents to tumor sites, we conducted HuIFN-b gene transfection of EPCs with a virus vector in vitro. In addition, when HuIFN-b was applied in the ex vivo culture of EPCs isolated from human cord blood, HuIFN-btransduced EPCs achieved efficient killing of the total population of SPC-A1 cells, indicating a bystander effect was elicited by HuIFN-b-transduced EPCs in vitro. When SCP-A1 cancer cells were coimplanted along with ex vivo cultivated EPCs subcutaneous injection in nude mice, the tumor growth was increased. However, the antitumor effect of IFN-b offset the tumor-progressive character of EPCs and the tumor growth, and the vascular density of tumor tissues increased by coimplanted EPCs were decreased upon IFN-b treatment. Finally, through this model, overall expression levels of VEGF in tumor tissues were decreased upon The fraction of PKH26 (red)-positive pixels or B. simplicifolia lectin B4 (green)-positive pixels was binarized to black and white, and a common threshold was set such that correct vascular morphology was represented with a minimum of background noise. *Po0.05, **Po0.01.
IFN-b treatment. Interestingly, strong VEGF expression by implanted
EPCs was decreased by IFN-b. As VEGF increases EPC mobilization from bone marrow into circulation, decrement of VEGF expression can be a critical control point. 8, 9 Therefore, our results showed for the first time that IFN-b inhibits tumor vasculogenesis by EPCs in vivo, suggesting that gene-transfected EPCs could be useful as a tumor-specific drug delivery system, especially if the tumor vasculature-promoting effect of EPCs can be blocked.
MATERIALS AND METHODS
Cell culture
The human embryonic kidney cell line 293T and human non-small cell lung carcinoma cells (SPC-A1), which were purchased from the American Type Culture Collection (Manassas, VA, USA), were maintained in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum at 37 1C in a CO 2 atmosphere.
Ex vivo cultivation of EPCs from cord blood
Mononuclear cells were isolated from the cord blood using the FicollHypaque density gradient centrifugation method as described before. 10 Isolated mononuclear cells (1 Â 10 7 cells per well) were plated into a sixwell plate coated with 0.1 mg ml À1 human fibronectin (Sigma, Oakville, Canada) and were incubated for 3 days. After that, nonadherent cells were removed and selected adherent cells were maintained in M199 medium supplemented with 20% fetal bovine serum (Life Technologies, Gaithersburg, MD, USA), 30 mg ml À1 endothelial cell growth supplements (Sigma), 90 mg ml À1 heparin (Sigma), and 1% antibiotics for 3 days. After 3 days of culture, nonadherent cells were removed by washing with phosphatebuffered saline (PBS), and new medium was again added to each well.
To confirm the EPCs phenotype, direct fluorescent staining was used to detect dual binding of fluorescein isothiocyanate (FITC)-labeled Ulex europaeus agglutinin 1 (ulex-lectin; Sigma) and DiI-labeled acetylated low-density lipoprotein (acLDL; Molecular Probes, Burlington, Canada) on attached adherent cells in day 4 culture. Cells were visualized with a fluorescent microscope, and adherent cells that stained positive for both FITC --Ulex-lectin and DiI-acLDL were considered to be EPCs. 10 A total of 10 randomly selected high-powered fields from 2 individual wells were examined in each sample, and the number of dual-staining cells was counted by an observer blinded to the patients' study group.
Viral infection
An HIV (human immunodeficiency virus)-based lentiviral vector encoding HuIFN-b was constructed and packaged by a method described by Wu et al. 11 Briefly, the lentivirus was produced by cotransfection into 293T cells with a plasmid encoding viral packaging components gag-pro, a plasmid encoding RT-IN, a plasmid encoding VSV-G and a transducing vector, which contain a gene encoding HuIFN-b driven by the cytomegalovirus promoter. Lentiviral infection was done as follows. EPCs were placed in a 24-well plate at 5 Â 10 5 cells per well. The following morning, cells were washed with PBS and were overlaid with medium containing 0.1% fetal bovine serum , 8 mg ml À1 Polybrene (Sigma H-9268, St Louis, MO, USA) and the lentivirus encoding the HuIFN-b gene. After 6 h of infection, we changed the medium with fresh medium containing 10% fetal bovine serum. Untreated EPCs was used as mock and the lentiviral vector as control.
Real-time PCR
Total RNA was isolated and transcribed into cDNA with RNeasy Mini kit (Qiagen, Hilden, Germany) and High-Capacity cDNA Reverse Transcription kits (Applied Biosystems, Foster City, CA, USA). The resulting cDNA was used as a template for real-time PCR along with primer/probe sets for HuIFN-b (TaqMan Gene Expression Assays; Applied Biosystems) and 2 Â TaqMan Universal PCR Master Mix (Applied Biosystems) according to the manufacturer's recommendations. The primer/probe sets for 18S were used as internal controls in the reactions and real-time PCR data were analyzed using sequence detector software (Applied Biosystems).
Immunoblotting
The expression of HuIFN-b or VEGF was measured by western blot using GAPDH (glyceraldehyde-3-phosphate) staining as a loading control. EPCs or tumor tissues were lysed in buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.5% NP-40, 1 mM DTT (dithiothreitol), 1 mM NaF, 1 mM Na 3 VO 4 and protease inhibitor cocktail (Roche Inc., Nutley, NJ, USA). Lysate (about 50 mg) was applied to SDS-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane. The membranes were first incubated with antibodies against GAPDH (Abcom, ab8245, 1:5000) and HuIFN-b (Abcom, ab31606, 1:500) or VEGF (Abcom, ab1316, 1:500), respectively, overnight at 4 1C, followed by 1 --h incubation with the appropriate secondary antibody consisting of horseradish peroxidase. Detection by enzyme-linked chemiluminescence (Pierce, Rockford, IL, USA) was performed according to the manufacturer's protocol.
HuIFN-b and VEGF detection by ELISA 
Immunofluorescent staining
For cryosectioning, the tumors were fixed in 4% paraformaldehyde, incubated in 30% sucrose in PBS overnight at 4 1C, embedded in optimal cutting temperature compound (Sakura Finetek Europe, Zoeter Woude, The Netherlands), and frozen at À70 1C. Tissue sections, cut with cryostat (Leica CM 1800, Heidelberg, Germany) at a thickness of 8 mm and dried on glass slides, were rinsed in PBS and then blocked with 10% normal goat serum or 0.3% Triton-X in PBS for 1 h. Tissue sections were incubated with mouse anti-human IFN-b monoclonal antibody (clone BV6, Chemicon, Temecula, CA, USA) or human VEGF-specific polyclonal rabbit antibody (R&D Systems) as primary antibodies overnight at 4 1C. Samples were washed and incubated with FITC-conjugated anti-mouse or rhodamineconjugated anti-goat antibodies (Molecular Probes) for 1 h at room temperature. Sections were treated with biotinylated B. simplicifolia lectin B4 (Vector Laboratories, Burlingame, CA, USA) and then with fluorescein streptavidin to identify murine endothelial cells according to the manufacturer's instructions. Finally, the sample was rinsed in PBS and mounted (DABCO; Sigma). Figures were taken using an inverted fluorescent microscope.
Statistical analysis
Values are expressed as means (s.e.m.). Differences between the experimental and control groups were analyzed by the Kruskal --Wallis test, followed by the Scheffe F test. Significance was established at Po0.05.
